First Time Loading...

Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 73.25 USD 0.33% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. [ Read More ]

The intrinsic value of one GILD stock under the Base Case scenario is 78.72 USD. Compared to the current market price of 73.25 USD, Gilead Sciences Inc is Undervalued by 7%.

Key Points:
GILD Intrinsic Value
Base Case
78.72 USD
Undervaluation 7%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Gilead Sciences Inc

Backtest GILD Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GILD stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Gilead's Strong HIV Market Dominance
2023-Q4 Earnings Call

Gilead's Strong HIV Market Dominance

Gilead Sciences revealed that despite a 2% year-over-year decline in sales due to lower prices from channel mix changes, sequential sales grew by 1%. In 2024, they predict a 4% growth in HIV sales, banking on treatment demand and HIV prevention. The first quarter tends to see a 10-12% decline due to inventory adjustments. Their HIV treatments, especially Biktarvy, continue strong performance, maintaining a dominant market share (over 70% in the U.S.). Liver disease sales were stable at $2.8 billion yearly. However, the oncology business excelled with a 24% year-over-year increase, exceeding $3 billion in annualized revenue, propelled by Trodelvy's success. The cell therapy sector approached $2 billion in 2023 with Kite leading the CAR T-cell therapy market globally. Despite some disappointments in clinical trials, such as EVOKE-01 not meeting its primary endpoint, Gilead's commitment to innovation persists.

Financials

Balance Sheet Decomposition
Gilead Sciences Inc

Current Assets 16.1B
Cash & Short-Term Investments 9.6B
Receivables 4.7B
Other Current Assets 1.8B
Non-Current Assets 46B
Long-Term Investments 1.2B
PP&E 5.3B
Intangibles 34.8B
Other Non-Current Assets 4.8B
Current Liabilities 11.3B
Accounts Payable 550m
Accrued Liabilities 7.7B
Other Current Liabilities 3B
Non-Current Liabilities 28B
Long-Term Debt 23.2B
Other Non-Current Liabilities 4.8B
Efficiency

Earnings Waterfall
Gilead Sciences Inc

Revenue
27.1B USD
Cost of Revenue
-6B USD
Gross Profit
21.1B USD
Operating Expenses
-12.9B USD
Operating Income
8.2B USD
Other Expenses
-2.5B USD
Net Income
5.7B USD

Free Cash Flow Analysis
Gilead Sciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

GILD Profitability Score
Profitability Due Diligence

Gilead Sciences Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Positive Gross Profit
Positive Operating Income
Positive 3-Year Average ROE
69/100
Profitability
Score

Gilead Sciences Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

GILD Solvency Score
Solvency Due Diligence

Gilead Sciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Short-Term Solvency
Average Altman Z-Score
Average D/E
50/100
Solvency
Score

Gilead Sciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GILD Price Targets Summary
Gilead Sciences Inc

Wall Street analysts forecast GILD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GILD is 87.56 USD with a low forecast of 69.69 USD and a high forecast of 127.05 USD.

Lowest
Price Target
69.69 USD
5% Downside
Average
Price Target
87.56 USD
20% Upside
Highest
Price Target
127.05 USD
73% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

GILD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

GILD Price
Gilead Sciences Inc

1M 1M
+2%
6M 6M
-2%
1Y 1Y
-10%
3Y 3Y
+20%
5Y 5Y
+33%
10Y 10Y
+35%
Annual Price Range
73.25
52w Low
71.58
52w High
87.29
Price Metrics
Average Annual Return 12.01%
Standard Deviation of Annual Returns 14.74%
Max Drawdown -30%
Shares Statistics
Market Capitalization 91.3B USD
Shares Outstanding 1 245 770 000
Percentage of Shares Shorted 1.77%

GILD Return Decomposition
Main factors of price return

What is price return decomposition?

GILD News

Other Videos

Last Important Events
Gilead Sciences Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Gilead Sciences Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Gilead Sciences Inc Logo
Gilead Sciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

91.3B USD

Dividend Yield

4.24%

Description

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 14,400 full-time employees. The firm is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The firm also sells and distributes generic versions of Epclusa and Harvoni in the United States. The company sells and distributes its products in the United States through the wholesale channel. The company operates in more than 35 countries worldwide.

Contact

CALIFORNIA
Foster City
333 Lakeside Dr
+16505743000.0
https://www.gilead.com/

IPO

1992-01-22

Employees

14 400

Officers

Chairman & CEO
Mr. Daniel P. O'Day
Executive VP & CFO
Mr. Andrew D. Dickinson
Executive VP of Corporate Affairs, General Counsel & Corporate Secretary
Ms. Deborah H. Telman
Chief Commercial Officer
Ms. Johanna Mercier
Chief Medical Officer
Dr. Merdad V. Parsey M.D., Ph.D.
Senior VP, Corporate Controller & Principal Accounting Officer
Ms. Sandra Patterson
Show More
Vice President of Investor Relations
Ms. Jacquie Ross C.F.A.
Executive Vice President of Human Resources
Ms. Jyoti K. Mehra
Senior Vice President of Research, Innovation & Portfolio
Dr. Linda Slanec Higgins Ph.D.
Senior Vice President of Commercial Operations of Australia, Canada, Europe
Dr. Rudolf Ertl
Show Less

See Also

Discover More
What is the Intrinsic Value of one GILD stock?

The intrinsic value of one GILD stock under the Base Case scenario is 78.72 USD.

Is GILD stock undervalued or overvalued?

Compared to the current market price of 73.25 USD, Gilead Sciences Inc is Undervalued by 7%.